Verona Pharma PLC (VRNA)
Stock Price:
$6.01 USD
0.18 (3.09%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
311.43M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-31.94M |
| Shares Out |
51.82M |
| EPS (ttm) |
-2.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$6.01 |
| Previous Close |
$5.83 |
| Change ($) |
0.18 |
| Change (%) |
3.09% |
| Day's Open |
5.82 |
| Day's Range |
5.82 - 6.39 |
| Day's Volume |
236,508 |
| 52-Week Range |
2.01 - 15.71 |
More Stats
| Market Cap |
311.43M |
| Enterprise Value |
281.62M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
51.82M |
| Float |
40.43M |
| EPS (basic) |
-30.30 |
| EPS (diluted) |
-2.34 |
| FCF / Share |
-0.36 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
145,239 |
| Short Ratio |
1.04 |
| Short % of Float |
0.36% |
| Beta |
-0.49 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
12.56 |
| Revenue |
n/a |
| Operating Income |
-41.08M |
| Net Income |
-31.94M |
| Free Cash Flow |
-38.22M |
| Net Cash |
29.81M |
| Net Cash / Share |
0.58 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-45.08% |
| ROE |
-99.94% |
| ROIC |
-148.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$18.89*
(214.31% upside)
Low
17.0
Current: $6.01
High
25.0
Target: 18.89
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -41.08 | -25.59 | -29.76 | -7.02 | -8.98 |
| Net Income | -31.94 | -19.90 | -20.50 | -5.02 | -7.50 |
| Shares Outstanding | 105 | 105 | 103 | 103 | - |
| Earnings Per Share | -30.30 | -18.90 | -23.40 | -15.00 | -37.10 |
| Operating Cash Flow | -38.18 | -22.70 | -21.51 | -7.12 | -7.06 |
| Capital Expenditures | -0.04 | -0.01 | -0.01 | -0.01 | - |
| Free Cash Flow | -38.22 | -22.71 | -21.52 | -7.13 | -7.06 |
| Cash & Equivalents | 30.76 | 64.70 | 80.26 | 39.79 | 3.52 |
| Total Debt | 0.95 | - | - | - | - |
| Net Cash / Debt | 29.81 | 64.70 | 80.26 | 39.79 | 3.52 |
| Assets | 45.14 | 74.75 | 89.50 | 46.14 | 7.84 |
| Liabilities | 11.27 | 11.33 | 9.62 | 11.67 | 2.41 |
| Book Value | 33.87 | 63.42 | 79.88 | 34.47 | 5.43 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Verona Pharma PLC |
| Country |
United Kingdom |
| Employees |
33 |
| CEO |
David S. Zaccardelli |
Stock Information
| Ticker Symbol |
VRNA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VRNA |
| IPO Date |
April 27, 2017 |
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.